ICON PLC Stock Euronext Dublin
Stocks
ICLR
IE0005711209
Biotechnology & Medical Research
| Market Cap | 13.02B 11.38B 10.5B 9.68B 18.24B 1,254B 18.65B 126B 49.37B 614B 48.91B 47.83B 2,114B | P/E 2026 * |
24x | P/E 2027 * | 19.7x |
|---|---|---|---|---|---|
| Enterprise Value | 15.41B 13.46B 12.42B 11.45B 21.59B 1,484B 22.07B 149B 58.41B 727B 57.86B 56.59B 2,502B | EV / Sales 2026 * |
1.91x | EV / Sales 2027 * | 1.77x |
| Free-Float |
99.56% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ICON PLC
| 1 day | -0.50% |
| Manager | Title | Age | Since |
|---|---|---|---|
Barry Balfe
CEO | Chief Executive Officer | 48 | 01/10/2025 |
Nigel Clerkin
DFI | Director of Finance/CFO | 53 | 01/10/2024 |
Ute Berger
CTO | Chief Tech/Sci/R&D Officer | - | 01/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
John Climax
CHM | Chairman | 73 | 01/11/2002 |
Ciaran Murray
CHM | Chairman | 63 | 01/03/2017 |
Eugene McCague
BRD | Director/Board Member | 67 | 04/10/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.50% | -8.66% | - | - | 13.02B | |
| -1.29% | -3.11% | -0.35% | +3.09% | 49.18B | |
| +3.90% | -0.39% | +386.06% | +593.85% | 39.58B | |
| -1.70% | +4.46% | +5.93% | +60.25% | 34.69B | |
| -2.01% | -0.76% | +28.41% | -8.01% | 34.42B | |
| +0.06% | +0.34% | +2.38% | +34.38% | 27.11B | |
| +0.46% | -3.49% | - | - | 16.21B | |
| -0.04% | -0.09% | +72.42% | +115.55% | 15.36B | |
| +1.12% | +1.91% | +14.54% | +19.16% | 14.05B | |
| -0.08% | -3.01% | +1,282.83% | +635.80% | 11.76B | |
| Average | -0.01% | -0.46% | +224.03% | +181.76% | 26.93B | |
| Weighted average by Cap. | -0.08% | -0.40% | +145.52% | +158.83% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.06B 7.04B 6.5B 5.99B 11.29B 776B 11.54B 77.67B 30.55B 380B 30.26B 29.6B 1,308B | 8.31B 7.27B 6.7B 6.18B 11.65B 801B 11.91B 80.13B 31.52B 392B 31.22B 30.54B 1,350B |
| Net income | 520M 454M 419M 386M 728M 50.07B 745M 5.01B 1.97B 24.52B 1.95B 1.91B 84.42B | 608M 532M 491M 452M 852M 58.58B 871M 5.86B 2.31B 28.69B 2.28B 2.23B 98.76B |
| Net Debt | 2.39B 2.08B 1.92B 1.77B 3.34B 230B 3.42B 22.99B 9.04B 113B 8.96B 8.76B 387B | 1.66B 1.45B 1.34B 1.23B 2.33B 160B 2.38B 16B 6.29B 78.28B 6.23B 6.1B 269B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
